Poxel : H2 likely to be marked by abundant newsflow
>€ 46m in cash at end-June - Yesterday evening, Poxel reported its sales and cash position for Q2 2020. Sales came in at € 4.8m (vs € 6.9m in 2019) generated entirely by the group’s partnership with Sumitomo for the development and marketing of Imeglimine in Japan.At end-June 2020, cash and cash equivalents totalled € 46m vs € 37.2m end-2019, benefiting notably from € 17.7m raised last May. Newsflow will be mainly of a clinical and regulatory kind - ...Poxel is a clinical-stage biopharmaceutical company focused on the development of treatments for type 2 diabetes and metabolic disease. Co.'s two drug candidates, Imeglimin and PXL770, are intended to complement and augment existing type 2 diabetes therapies, including in patients who no longer fully respond to such therapies, with the goal of helping patients better control their type 2 diabetes and reduce potentially disabling or fatal complications.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.